Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Caribou Biosciences (CRBU) Accumulated Depreciation & Amortization (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $3.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 8.02% to $3.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.0 million, a 8.02% increase, with the full-year FY2024 number at $3.9 million, up 11.4% from a year prior.
  • Accumulated Depreciation & Amortization was $3.0 million for Q3 2025 at Caribou Biosciences, up from $2.3 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $3.9 million in Q4 2024 to a low of $308000.0 in Q1 2022.
  • A 5-year average of $1.7 million and a median of $1.2 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: plummeted 68.22% in 2021, then skyrocketed 149.55% in 2023.
  • Caribou Biosciences' Accumulated Depreciation & Amortization stood at $984000.0 in 2021, then skyrocketed by 64.84% to $1.6 million in 2022, then soared by 117.32% to $3.5 million in 2023, then increased by 11.4% to $3.9 million in 2024, then decreased by 24.55% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Accumulated Depreciation & Amortization are $3.0 million (Q3 2025), $2.3 million (Q2 2025), and $1.2 million (Q1 2025).